View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Budapest Korányi S. u. 2/A 1083
Open access

A malignus tumorok és a thrombosis között kétirányú a kapcsolat. Rosszindulatú daganatban gyakoribbak a thromboemboliás történések, az alvadási rendszer aktivációja a tumoros folyamat progresszióját, valamint a metasztázisképződést segíti elő. A thromboembolia kialakulása lényegesen rontja a daganatos beteg túlélési esélyeit. A tumoros betegek között a második leggyakoribb halálok a thromboemboliás történés. Ennek hátterében több tényező is áll, például az új tumorellenes gyógyszerek egy része sokkal kifejezettebben fokozza a thrombosis kialakulásának esélyét, mint a hagyományos kemoterápiás szerek. A thrombosiskockázat mértéke függ a daganat típusától és igen nagy egyéni különbségeket is mutat. Adott beteget tekintve a thrombosishajlam változik a betegség lefolyása során is. A malignus daganat miatt elvégzett sebészeti beavatkozások is fokozott thrombosiskockázatot eredményeznek. Egyre inkább középpontba kerül a tumoros betegek thrombosiskockázatának felmérése, és több ajánlás is foglalkozik a malignus daganatban szenvedő beteg thrombosisának megelőzésével és kezelésével. Orv. Hetil., 2012, 153, 934–947.

  • Trousseau, A.: Plegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris, 1865, 5, 281–332.

    Trousseau A. , 'Plegmasia alba dolens ' (1865 ) 5 Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris : 281 -332.

    • Search Google Scholar
  • Varki, A.: Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood, 2007, 110, 1723–1729.

    Varki A. , 'Trousseau’s syndrome: multiple definitions and multiple mechanisms ' (2007 ) 110 Blood : 1723 -1729.

    • Search Google Scholar
  • Næss, I. A., Christiansen, S. C., Romundstad, P., et al.: Incidence and mortality of venous thrombosis: a population-based study. J. Thromb. Haemost., 2007, 5, 692–699.

    Romundstad P. , 'Incidence and mortality of venous thrombosis: a population-based study ' (2007 ) 5 J. Thromb. Haemost. : 692 -699.

    • Search Google Scholar
  • Conget, F., Otero, R., Jiménez, D., et al.: Short-term clinical outcome after acute symptomatic pulmonary embolism. Thromb. Haemost., 2008, 100, 937–942.

    Jiménez D. , 'Short-term clinical outcome after acute symptomatic pulmonary embolism ' (2008 ) 100 Thromb. Haemost. : 937 -942.

    • Search Google Scholar
  • Hunt, B. J.: Awareness and politics of venous thromboembolism in the United Kingdom. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 398–399.

    Hunt B. J. , 'Awareness and politics of venous thromboembolism in the United Kingdom ' (2008 ) 28 Arterioscler. Thromb. Vasc. Biol. : 398 -399.

    • Search Google Scholar
  • Mohr, D., Silverstein, M., Heit, J., et al.: The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clinic Proceedings, 2000, 75, 1249–1256.

    Heit J. , 'The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study ' (2000 ) 75 Mayo Clinic Proceedings : 1249 -1256.

    • Search Google Scholar
  • Rosovsky, R., Lee, A. Y.: Evidence-based mini-review: should all patients with idiopathic venous thromboembolic events be screened extensively for occult malignancy? Hematology Am. Soc. Hematol. Educ. Program, 2010, 2010, 150–152.

    Lee A. Y. , 'Evidence-based mini-review: should all patients with idiopathic venous thromboembolic events be screened extensively for occult malignancy? ' (2010 ) 2010 Hematology Am. Soc. Hematol. Educ. Program : 150 -152.

    • Search Google Scholar
  • Blom, J. W., Doggen, C. J., Osanto, S., et al.: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 2005, 293, 715–722.

    Osanto S. , 'Malignancies, prothrombotic mutations, and the risk of venous thrombosis ' (2005 ) 293 JAMA : 715 -722.

    • Search Google Scholar
  • Levitan, N., Dowlati, A., Remick, S. C., et al.: Rates of initial and recurrent thromboembolic disease among patients with malignancy vs those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore), 1999, 78, 285–291.

    Remick S. C. , 'Rates of initial and recurrent thromboembolic disease among patients with malignancy vs those without malignancy. Risk analysis using Medicare claims data ' (1999 ) 78 Medicine (Baltimore) : 285 -291.

    • Search Google Scholar
  • Stein, P. D., Beemath, A., Meyers, F. A., et al.: Incidence of venous thromboembolism in patients hospitalized with cancer. Am. J. Med., 2006, 119, 60–68.

    Meyers F. A. , 'Incidence of venous thromboembolism in patients hospitalized with cancer ' (2006 ) 119 Am. J. Med. : 60 -68.

    • Search Google Scholar
  • Lee, A. Y., Levine, M. N.: Venous thromboembolism and cancer: risks and outcomes. Circulation, 2003, 107 (23 Suppl. 1), I17–I21.

    Levine M. N. , 'Venous thromboembolism and cancer: risks and outcomes ' (2003 ) 107 Circulation : I17 -I21.

    • Search Google Scholar
  • Sørensen, H. T., Mellemkjaer, L., Olsen, J. H., et al.: Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med., 2000, 343, 1846–1850.

    Olsen J. H. , 'Prognosis of cancers associated with venous thromboembolism ' (2000 ) 343 N. Engl. J. Med. : 1846 -1850.

    • Search Google Scholar
  • Lyman, G. H.: Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer, 2011, 117, 1334–1349.

    Lyman G. H. , 'Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis ' (2011 ) 117 Cancer : 1334 -1349.

    • Search Google Scholar
  • Agnelli, G., Bolis, G., Capussotti, L., et al.: A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann. Surg., 2006, 243, 89–95.

    Capussotti L. , 'A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project ' (2006 ) 243 Ann. Surg. : 89 -95.

    • Search Google Scholar
  • Noble, S., Pasi, J.: Epidemiology and pathophysiology of cancer-associated thrombosis. Br. J. Cancer, 2010, 102 (Suppl. 1), S2–S9.

    Pasi J. , 'Epidemiology and pathophysiology of cancer-associated thrombosis ' (2010 ) 102 Br. J. Cancer : S2 -S9.

    • Search Google Scholar
  • Dipasco, P. J., Misra, S., Koniaris, L. G., et al.: Thrombophilic state in cancer, Part I: Biology, incidence, and risk factors. J. Surg. Oncol., 2011, 104, 316–322.

    Koniaris L. G. , 'Thrombophilic state in cancer, Part I: Biology, incidence, and risk factors ' (2011 ) 104 J. Surg. Oncol. : 316 -322.

    • Search Google Scholar
  • Hoffman, R., Haim, N., Brenner, B.: Cancer and thrombosis revisited. Blood Rev., 2001, 15, 61–67.

    Brenner B. , 'Cancer and thrombosis revisited ' (2001 ) 15 Blood Rev. : 61 -67.

  • Oleksowicz, L., Bhagwati, N., DeLeon-Fernandez, M.: Deficient activity of von Willebrand’s factor-cleaving protease in patients with disseminated malignancies. Cancer Res., 1999, 59, 2244–2250.

    DeLeon-Fernandez M. , 'Deficient activity of von Willebrand’s factor-cleaving protease in patients with disseminated malignancies ' (1999 ) 59 Cancer Res. : 2244 -2250.

    • Search Google Scholar
  • Boccaccio, C., Comoglio, P. M.: Genetic link between cancer and thrombosis. J. Clin. Oncol., 2009, 27, 4827–4833.

    Comoglio P. M. , 'Genetic link between cancer and thrombosis ' (2009 ) 27 J. Clin. Oncol. : 4827 -4833.

    • Search Google Scholar
  • Rodrigues, C. A., Ferrarotto, R., Kalil Filho, R., et al.: Venous thromboembolism and cancer: a systematic review. J. Thromb. Thrombolysis, 2010, 30, 67–78.

    Kalil Filho R. , 'Venous thromboembolism and cancer: a systematic review ' (2010 ) 30 J. Thromb. Thrombolysis : 67 -78.

    • Search Google Scholar
  • Franchini, M., Mannucci, P. M.: Thrombin and cancer: from molecular basis to therapeutic implications. Semin. Thromb. Hemost., 2012, 38, 95–101.

    Mannucci P. M. , 'Thrombin and cancer: from molecular basis to therapeutic implications ' (2012 ) 38 Semin. Thromb. Hemost. : 95 -101.

    • Search Google Scholar
  • Karimi, M., Cohan, N.: Cancer-associated thrombosis. Open Cardiovasc. Med. J., 2010, 4, 78–82.

    Cohan N. , 'Cancer-associated thrombosis ' (2010 ) 4 Open Cardiovasc. Med. J. : 78 -82.

  • Khorana, A. A., Francis, C. W., Culakova, E., et al.: Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer, 2007, 110, 2339–2346.

    Culakova E. , 'Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients ' (2007 ) 110 Cancer : 2339 -2346.

    • Search Google Scholar
  • Agnelli, G., Verso, M.: Management of venous thromboembolism in patients with cancer. J. Thromb. Haemost., 2011, 9 (Suppl. 1), 316–324.

    Verso M. , 'Management of venous thromboembolism in patients with cancer ' (2011 ) 9 J. Thromb. Haemost. : 316 -324.

    • Search Google Scholar
  • Ay, C., Pabinger, I.: Tests predictive of thrombosis in cancer. Thromb. Res., 2010, 125 (Suppl. 2), S12–S15.

    Pabinger I. , 'Tests predictive of thrombosis in cancer ' (2010 ) 125 Thromb. Res. : S12 -S15.

    • Search Google Scholar
  • Khorana, A. A., Kuderer, N. M., Culakova, E., et al.: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 2008, 111, 4902–4907.

    Culakova E. , 'Development and validation of a predictive model for chemotherapy-associated thrombosis ' (2008 ) 111 Blood : 4902 -4907.

    • Search Google Scholar
  • Sud, R., Khorana, A. A.: Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb. Res., 2009, 123 (Suppl. 4), S18–S21.

    Khorana A. A. , 'Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model ' (2009 ) 123 Thromb. Res. : S18 -S21.

    • Search Google Scholar
  • McRae, S.: Pulmonary embolism. Aust. Fam. Physician, 2010, 39, 462–466.

    McRae S. , 'Pulmonary embolism ' (2010 ) 39 Aust. Fam. Physician : 462 -466.

  • Geerts, W. H., Bergqvist, D., Pineo, G. F., et al.: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th ed.). Chest, 2008, 133 (6 Suppl.), 381S–453S.

    Pineo G. F. , 'Prevention of venous thromboembolism: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th ed.) ' (2008 ) 133 Chest : 381S -453S.

    • Search Google Scholar
  • Wells, P. S.: Advances in the diagnosis of venous thromboembolism. J. Thromb. Thrombolysis, 2006, 21, 31–40.

    Wells P. S. , 'Advances in the diagnosis of venous thromboembolism ' (2006 ) 21 J. Thromb. Thrombolysis : 31 -40.

    • Search Google Scholar
  • Streiff, M. B.: The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb. Res., 2010, 125 (Suppl. 2), S128–S133.

    Streiff M. B. , 'The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients ' (2010 ) 125 Thromb. Res. : S128 -S133.

    • Search Google Scholar
  • Carrier, M., Lee, A. Y., Bates, S. M., et al.: Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thromb. Res., 2008, 123, 177–183.

    Bates S. M. , 'Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients ' (2008 ) 123 Thromb. Res. : 177 -183.

    • Search Google Scholar
  • Pikwer, A., Åkeson, J., Lindgren, S.: Complications associated with peripheral or central routes for central venous cannulation. Anaesthesia, 2012, 67, 65–71.

    Lindgren S. , 'Complications associated with peripheral or central routes for central venous cannulation ' (2012 ) 67 Anaesthesia : 65 -71.

    • Search Google Scholar
  • Anderson, F. A., Spencer, F. A.: Risk factors for venous thromboembolism. Circulation, 2003, 107 (Suppl. 1), 9–16.

    Spencer F. A. , 'Risk factors for venous thromboembolism ' (2003 ) 107 Circulation : 9 -16.

  • Prandoni, P., Falanga, A., Piccioli, A.: Cancer and venous thromboembolism. Lancet Oncol., 2005, 6, 401–410.

    Piccioli A. , 'Cancer and venous thromboembolism ' (2005 ) 6 Lancet Oncol. : 401 -410.

  • Losonczy, H., Tar, A.: Results of ENDORSE-2-HUNGARIA study. Repeated assessment of the prevalence of venous thromboembolism risk and prophylaxis in acute hospital care setting. [Az ENDORSE-2-HUNGARIA vizsgálat eredményei. Az akut kórházi betegek vénás thromboembolia kockázatának és profilaxisának ismételt hazai felmérése.] Orv. Hetil., 2010, 151, 843–852. [Hungarian]

    Tar A. , 'Results of ENDORSE-2-HUNGARIA study. Repeated assessment of the prevalence of venous thromboembolism risk and prophylaxis in acute hospital care setting. [Az ENDORSE-2-HUNGARIA vizsgálat eredményei. Az akut kórházi betegek vénás thromboembolia kockázatának és profilaxisának ismételt hazai felmérése.] ' (2010 ) 151 Orv. Hetil. : 843 -852.

    • Search Google Scholar
  • Bona, R. D.: Thrombotic complications of central venous catheters in cancer patients. Semin. Thromb. Hemost., 1999, 25, 147–155.

    Bona R. D. , 'Thrombotic complications of central venous catheters in cancer patients ' (1999 ) 25 Semin. Thromb. Hemost. : 147 -155.

    • Search Google Scholar
  • Walshe, L. J., Malak, S. F., Eagan, J., et al.: Complication rates among cancer patients with peripherally inserted central catheters. J. Clin. Oncol., 2002, 20, 3276–3281.

    Eagan J. , 'Complication rates among cancer patients with peripherally inserted central catheters ' (2002 ) 20 J. Clin. Oncol. : 3276 -3281.

    • Search Google Scholar
  • Couban, S., Goodyear, M., Burnell, M., et al.: A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. Blood, 2002, 100, 703a.

    Burnell M. , 'A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer ' (2002 ) 100 Blood : 703a -.

    • Search Google Scholar
  • Blom, J. W., Vanderschoot, J. P., Oostindiër, M. J., et al.: Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J. Thromb. Haemost., 2006, 4, 529–535.

    Oostindiër M. J. , 'Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study ' (2006 ) 4 J. Thromb. Haemost. : 529 -535.

    • Search Google Scholar
  • Haddad, T. C., Greeno, E. W.: Chemotherapy-induced thrombosis. Thromb. Res., 2006, 118, 555–568.

    Greeno E. W. , 'Chemotherapy-induced thrombosis ' (2006 ) 118 Thromb. Res. : 555 -568.

  • Lee, A., Levine, M.: The thrombophilic state induced by therapeutic agents in the cancer patient. Semin. Thromb. Hemost., 1999, 25, 137–145.

    Levine M. , 'The thrombophilic state induced by therapeutic agents in the cancer patient ' (1999 ) 25 Semin. Thromb. Hemost. : 137 -145.

    • Search Google Scholar
  • Numico, G., Garrone, O., Dongiovanni, V., et al.: Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer, 2005, 103, 994–999.

    Dongiovanni V. , 'Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine ' (2005 ) 103 Cancer : 994 -999.

    • Search Google Scholar
  • Zamagni, E., Brioli, A. P., Zannetti, B., et al.: Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin. Thromb. Hemost., 2011, 37, 209–219.

    Zannetti B. , 'Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis ' (2011 ) 37 Semin. Thromb. Hemost. : 209 -219.

    • Search Google Scholar
  • Nalluri, S. R., Chu, D., Keresztes, R., et al.: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA, 2008, 300, 2277–2285.

    Keresztes R. , 'Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis ' (2008 ) 300 JAMA : 2277 -2285.

    • Search Google Scholar
  • Bennett, C. L., Silver, S. M., Djulbegovic, B., et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA, 2008, 299, 914–924.

    Djulbegovic B. , 'Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia ' (2008 ) 299 JAMA : 914 -924.

    • Search Google Scholar
  • Bergqvist, D.: Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis. J. Surg. Oncol., 2007, 95, 167–174.

    Bergqvist D. , 'Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis ' (2007 ) 95 J. Surg. Oncol. : 167 -174.

    • Search Google Scholar
  • Khorana, A. A., Francis, C. W., Culakova, E., et al.: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost., 2007, 5, 632–634.

    Culakova E. , 'Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy ' (2007 ) 5 J. Thromb. Haemost. : 632 -634.

    • Search Google Scholar
  • Falanga, A., Marchetti, M.: Venous thromboembolism in the hematologic malignancies. J. Clin. Oncol., 2009, 27, 4848–4857.

    Marchetti M. , 'Venous thromboembolism in the hematologic malignancies ' (2009 ) 27 J. Clin. Oncol. : 4848 -4857.

    • Search Google Scholar
  • Melillo, L., Grandone, E., Colaizzo, D., et al.: Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: A single center experience of 114 patients at diagnosis. Acta Haematol., 2007, 117, 215–220.

    Colaizzo D. , 'Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: A single center experience of 114 patients at diagnosis ' (2007 ) 117 Acta Haematol. : 215 -220.

    • Search Google Scholar
  • Rickles, F. R., Falanga, A., Montesinos, P., et al.: Bleeding and thrombosis in acute leukemia: What does the future of therapy look like? Thromb. Res., 2007, 120 (Suppl. 2), S99–S106.

    Montesinos P. , 'Bleeding and thrombosis in acute leukemia: What does the future of therapy look like? ' (2007 ) 120 Thromb. Res. : S99 -S106.

    • Search Google Scholar
  • Wun, T., White, R. H.: Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. Thromb. Res., 2010, 125 (Suppl. 2), S96–S102.

    White R. H. , 'Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma ' (2010 ) 125 Thromb. Res. : S96 -S102.

    • Search Google Scholar
  • Khorana, A. A., Francis, C. W., Culakova, E., et al.: Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer, 2005, 104, 2822–2829.

    Culakova E. , 'Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study ' (2005 ) 104 Cancer : 2822 -2829.

    • Search Google Scholar
  • Eby, C.: Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br. J. Haematol., 2009, 145, 151–163.

    Eby C. , 'Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias ' (2009 ) 145 Br. J. Haematol. : 151 -163.

    • Search Google Scholar
  • Rajkumar, S. V., Blood, E., Vesole, D., et al.: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol., 2006, 24, 431–436.

    Vesole D. , 'Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group ' (2006 ) 24 J. Clin. Oncol. : 431 -436.

    • Search Google Scholar
  • Palumbo, A., Bertola, A., Falco, P., et al.: Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol. J., 2004, 5, 318–324.

    Falco P. , 'Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma ' (2004 ) 5 Hematol. J. : 318 -324.

    • Search Google Scholar
  • Falanga, A., Marchetti, M., Vignoli, A., et al.: V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp. Hematol., 2007, 35, 702–711.

    Vignoli A. , 'V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules ' (2007 ) 35 Exp. Hematol. : 702 -711.

    • Search Google Scholar
  • Cortelazzo, S., Viero, P., Finazzi, G., et al.: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol., 1990, 8, 556–562.

    Finazzi G. , 'Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia ' (1990 ) 8 J. Clin. Oncol. : 556 -562.

    • Search Google Scholar
  • Vianello, F., Battisti, A., Cella, G., et al.: Defining the thrombotic risk in patients with myeloproliferative neoplasms. Scientific World Journal, 2011, 11, 1131–1137.

    Cella G. , 'Defining the thrombotic risk in patients with myeloproliferative neoplasms ' (2011 ) 11 Scientific World Journal : 1131 -1137.

    • Search Google Scholar
  • Gonsalves, A., Carrier, M., Wells, P. S., et al.: Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J. Thromb. Haemost., 2008, 6, 1468–1473.

    Wells P. S. , 'Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation ' (2008 ) 6 J. Thromb. Haemost. : 1468 -1473.

    • Search Google Scholar
  • Lyman, G. H., Khorana, A. A., Falanga, A., et al.: American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol., 2007, 25, 5490–5505.

    Falanga A. , 'American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer ' (2007 ) 25 J. Clin. Oncol. : 5490 -5505.

    • Search Google Scholar
  • Farge, D., Durant, C., Villiers, S., et al.: Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb. Res., 2010, 125 (Suppl. 2), S108–S116.

    Villiers S. , 'Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients ' (2010 ) 125 Thromb. Res. : S108 -S116.

    • Search Google Scholar
  • Mandalà, M., Falanga, A., Roila, F. ESMO Guidelines Working Group: Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann. Oncol., 2009, 20 (Suppl. 4), 182–184.

    Roila F. , 'Management of venous thromboembolism in cancer patients: ESMO clinical recommendations ' (2009 ) 20 Ann. Oncol. : 182 -184.

    • Search Google Scholar
  • Khorana, A. A, Streiff, M. B., Farge, D., et al.: Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J. Clin. Oncol., 2009, 27, 4919–4926.

    Farge D. , 'Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action ' (2009 ) 27 J. Clin. Oncol. : 4919 -4926.

    • Search Google Scholar
  • Pfliegler, G. (ed.): Risk assessment and treatment of thromboembolism. Professional guideline of the Ministry of Health. [A thromboemboliák kockázatának csökkentése és kezelése. Az Egészségügyi Minisztérium szakmai irányelve.] Egészségügyi Minisztérium, Budapest, 2010, 80–88. [Hungarian]

    Pfliegler G. , 'Risk assessment and treatment of thromboembolism. Professional guideline of the Ministry of Health. [A thromboemboliák kockázatának csökkentése és kezelése. Az Egészségügyi Minisztérium szakmai irányelve.] ' (2010 ) Egészségügyi Minisztérium, Budapest : 80 -88.

    • Search Google Scholar
  • Khorana, A. A.: Cancer and thrombosis: implications of published guidelines for clinical practice. Ann. Oncol., 2009, 20, 1619–1630.

    Khorana A. A. , 'Cancer and thrombosis: implications of published guidelines for clinical practice ' (2009 ) 20 Ann. Oncol. : 1619 -1630.

    • Search Google Scholar
  • Khorana, A. A.: Risk assessment and prophylaxis for VTE in cancer patients. J. Natl. Compr. Canc. Netw., 2011, 9, 789–797.

    Khorana A. A. , 'Risk assessment and prophylaxis for VTE in cancer patients ' (2011 ) 9 J. Natl. Compr. Canc. Netw. : 789 -797.

    • Search Google Scholar
  • Er, O., Zacharski, L.: Management of cancer-associated venous thrombosis. Vasc. Health Risk Manag., 2006, 2, 351–356.

    Zacharski L. , 'Management of cancer-associated venous thrombosis ' (2006 ) 2 Vasc. Health Risk Manag. : 351 -356.

    • Search Google Scholar
  • Huo, M. H., Muntz, J.: Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. Clin. Ther., 2009, 31, 1129–1141.

    Muntz J. , 'Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review ' (2009 ) 31 Clin. Ther. : 1129 -1141.

    • Search Google Scholar
  • Agnelli, G., Bergqvist, D., Cohen, A. T., et al.; PEGASUS investigators: Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br. J. Surg., 2005, 92, 1212–1220.

    Cohen A. T. , 'Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery ' (2005 ) 92 Br. J. Surg. : 1212 -1220.

    • Search Google Scholar
  • Debourdeau, P., Kassab Chahmi, D., Le Gal, G.: 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann. Oncol., 2009, 20, 1459–1471.

    Gal G. , '2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group ' (2009 ) 20 Ann. Oncol. : 1459 -1471.

    • Search Google Scholar
  • Lee, A. Y.: Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am. Soc. Hematol. Educ. Program, 2010, 2010, 144–149.

    Lee A. Y. , 'Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants ' (2010 ) 2010 Hematology Am. Soc. Hematol. Educ. Program : 144 -149.

    • Search Google Scholar
  • Lee, A. Y., Levine, M. N., Baker, R. I., et al.: Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med., 2003, 349, 146–153.

    Baker R. I. , 'Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer ' (2003 ) 349 N. Engl. J. Med. : 146 -153.

    • Search Google Scholar
  • Selby, R., Geerts, W.: Prevention of venous thromboembolism: consensus, controversies, and challenges. Hematology Am. Soc. Hematol. Educ. Program, 2009, 2009, 286–292.

    Geerts W. , 'Prevention of venous thromboembolism: consensus, controversies, and challenges ' (2009 ) 2009 Hematology Am. Soc. Hematol. Educ. Program : 286 -292.

    • Search Google Scholar
  • DeFeo, K., Hayes, C., Chernick, M., et al.: Use of dabigatran etexilate to reduce breast cancer progression. Cancer Biol. Ther., 2010, 10, 1001–1008.

    Chernick M. , 'Use of dabigatran etexilate to reduce breast cancer progression ' (2010 ) 10 Cancer Biol. Ther. : 1001 -1008.

    • Search Google Scholar
  • Kuderer, N. M., Khorana, A. A., Lyman, G. H., et al.: A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer, 2007, 110, 1149–1161.

    Lyman G. H. , 'A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications ' (2007 ) 110 Cancer : 1149 -1161.

    • Search Google Scholar
  • Cunningham, M. S., Preston, R. J., O’Donnell, J. S.: Does antithrombotic therapy improve survival in cancer patients? Blood Rev., 2009, 23, 129–135.

    O’Donnell J. S. , 'Does antithrombotic therapy improve survival in cancer patients? ' (2009 ) 23 Blood Rev. : 129 -135.

    • Search Google Scholar
  • Mousa, S. A., Petersen, L. J.: Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb. Haemost., 2009, 102, 258–267.

    Petersen L. J. , 'Anti-cancer properties of low-molecular-weight heparin: preclinical evidence ' (2009 ) 102 Thromb. Haemost. : 258 -267.

    • Search Google Scholar
  • Szende, B., Paku, S., Rácz, G., et al.: Effect of fraxiparine and heparin on experimental tumor metastasis in mice. Anticancer Res., 2005, 25, 2869–2872.

    Rácz G. , 'Effect of fraxiparine and heparin on experimental tumor metastasis in mice ' (2005 ) 25 Anticancer Res. : 2869 -2872.

    • Search Google Scholar
  • Mousa, S. A.: Are low molecular weight heparins the same? Methods Mol. Med., 2004, 93, 49–59.

    Mousa S. A. , 'Are low molecular weight heparins the same? ' (2004 ) 93 Methods Mol. Med. : 49 -59.

    • Search Google Scholar
  • Meyer, G., Besse, B., Friard, S., et al.: Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours. Rev. Mal. Respir., 2011, 28, 654–659.

    Friard S. , 'Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours ' (2011 ) 28 Rev. Mal. Respir. : 654 -659.

    • Search Google Scholar
The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.
Mendeley citation style is available HERE.

Főszerkesztő - Editor-in-Chief:
 
Zoltán PAPP (professor emeritus, Semmelweis Egyetem, Szülészeti és Nőgyógyászati Klinika, Budapest)

Read the professional career of Zoltán PAPP HERE.

All scientific publications of Zoltán PAPP are collected in the Hungarian Scientific Bibliography.

Főszerkesztő-helyettesek - Assistant Editors-in-Chief: 

  • Erzsébet FEHÉR (professor emeritus, Semmelweis Egyetem, Anatómiai, Szövet- és Fejlődéstani Intézet)
  • Krisztina HAGYMÁSI (egyetemi docens, Semmelweis Egyetem, I. Sebészeti és Intervenciós Gasztroenterológiai Klinika, Budapest)

Főmunkatársak - Senior Editorial Specialists:

  • László KISS (a Debreceni Egyetem habilitált doktora)
  • Gabriella LENGYEL (ny. egyetemi docens, Semmelweis Egyetem, I. Sebészeti és Intervenciós Gasztroenterológiai Klinika, Budapest)
  • Alajos PÁR (professor emeritus, Pécsi Tudományegyetem, I. Belgyógyászati Klinika)

 A Szerkesztőbizottság tagjai – Members of the Editorial Board:

  • Péter ANDRÉKA (főigazgató, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
  • Géza ÁCS Jr. (egyetemi tanár Floridában)
  • Csaba BALÁZS (egyetemi tanár, Budai Endokrinközpont, Budapest)
  • Péter BENCSIK (volt folyóirat-kiadás vezető, Akadémiai Kiadó, Budapest)
  • Zoltán BENYÓ (egyetemi tanár, Semmelweis Egyetem, Transzlációs Medicina Intézet, Budapest)
  • Dániel BERECZKI (egyetemi tanár, Semmelweis Egyetem, Neurológiai Klinika, Budapest)
  • Anna BLÁZOVICS (professor emeritus, Semmelweis Egyetem, Farmakognóziai Intézet, Budapest)
  • Elek DINYA (professor emeritus, biostatisztikus, Semmelweis Egyetem, Budapest)
  • Attila DOBOZY (professor emeritus, Szegedi Tudományegyetem, Bőrgyógyászati Klinika, Szeged)
  • András FALUS (professor emeritus, Semmelweis Egyetem, Genetikai, Sejt- és Immunbiológiai Intézet, Budapest)
  • Csaba FARSANG (egyetemi tanár, Szent Imre Oktató Kórház, Belgyógyászati Osztály, Budapest)
  • János FAZAKAS (egyetemi docens, Semmelweis Egyetem, Transzplantációs és Sebészeti Klinika, Budapest)
  • Béla FÜLESDI (egyetemi tanár, Debreceni Egyetem, Aneszteziológiai és Intenzív Terápiás Klinika, Debrecen)
  • Beáta GASZTONYI (egyetemi magántanár, kórházi főorvos, Zala Megyei Kórház, Belgyógyászat, Zalaegerszeg)
  • István GERGELY (egyetemi docens, Marosvásárhelyi Orvosi és Gyógyszerészeti Egyetem, Románia)
  • Judit GERVAIN (osztályvezető főorvos, Fejér Megyei Szent György Kórház, Belgyógyászat, Székesfehérvár)
  • Béla GÖMÖR (professor emeritus, Budai Irgalmasrendi Kórház, Reumatológiai Osztály, Budapest)
  • László GULÁCSI (egyetemi tanár, Óbudai Egyetem, Egészségügyi Közgazdaságtan Tanszék, Budapest)
  • János HANKISS (professor emeritus, Markusovszky Lajos Oktató Kórház, Belgyógyászati Osztály, Szombathely)
  • Örs Péter HORVÁTH (professor emeritus, Pécsi Tudományegyetem, Sebészeti Klinika, Pécs)
  • Béla HUNYADY (egyetemi tanár, Somogy Megyei Kaposi Mór Kórház, Belgyógyászat, Kaposvár)
  • Péter IGAZ (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
  • Ferenc JAKAB (c. egyetemi tanár, Uzsoki Utcai Kórház, Sebészet, Budapest)
  • András JÁNOSI (c. egyetemi tanár, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
  • György JERMENDY (egyetemi tanár, Bajcsy-Zsilinszky Kórház, Belgyógyászat, Budapest)
  • László KALABAY (egyetemi tanár, Semmelweis Egyetem, Családorvosi Tanszék, Budapest)
  • János KAPPELMAYER (egyetemi tanár, Debreceni Egyetem, Laboratóriumi Medicina Intézet, Debrecen)
  • Éva KELLER (ny. egyetemi tanár, Semmelweis Egyetem, Igazságügyi és Biztosítás-orvostani Intézet, Budapest)
  • Mátyás KELTAI (ny. egyetemi docens, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
  • András KISS (egyetemi tanár, Semmelweis Egyetem, II. Patológiai Intézet, Budapest)
  • László KÓBORI (egyetemi tanár, Semmelweis Egyetem, Transzplantációs és Sebészeti Klinika, Budapest)
  • Lajos KULLMANN (ny. egyetemi tanár, Országos Rehabilitációs Intézet, Budapest)
  • Emese MEZŐSI (egyetemi tanár, Pécsi Tudományegyetem, I. Belgyógyászati Klinika, Pécs)
  • József MOLNÁR (professor emeritus, Szegedi Tudományegyetem, Mikrobiológiai és Immunológiai Intézet, Szeged)
  • Péter MOLNÁR (professor emeritus, Debreceni Egyetem, Magatartástudományi Intézet, Debrecen)
  • Györgyi MŰZES (egyetemi docens, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Bálint NAGY (egyetemi tanár, Debreceni Egyetem, Humángenetikai Tanszék, Debrecen)
  • Endre NAGY (egyetemi tanár, Debreceni Egyetem, Belgyógyászati Intézet, Debrecen) 
  • Péter NAGY (egyetemi tanár, Semmelweis Egyetem, I. Patológiai és Kísérleti Rákkutató Intézet, Budapest)
  • Viktor NAGY (főorvos, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Zoltán Zsolt NAGY (egyetemi tanár, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
  • Balázs NEMES (egyetemi docens, Debreceni Egyetem, Transzplantációs Tanszék, Debrecen)
  • Attila PATÓCS (tudományos főmunkatárs, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Gabriella PÁR (egyetemi docens, Pécsi Tudományegyetem, I. Belgyógyászati Klinika)
  • György PFLIEGLER (egyetemi tanár, Debreceni Egyetem, Ritka Betegségek Tanszéke, Debrecen)
  • István RÁCZ (egyetemi tanár, főorvos, Petz Aladár Megyei Oktató Kórház, Belgyógyászat, Győr)
  • Imre ROMICS (professor emeritus, Semmelweis Egyetem, Urológiai Klinika, Budapest)
  • László Jr. ROMICS (Angliában dolgozik) 
  • Imre RURIK (egyetemi tanár, Debreceni Egyetem, Családorvosi és Foglalkozás-egészségügyi Tanszék, Debrecen)
  • Zsuzsa SCHAFF (professor emeritus, Semmelweis Egyetem, II. Patológiai Intézet, Budapest)
  • Péter SCHMIDT (házi gyermekorvos, Győr)
  • Kornél SIMON (ny. osztályvezető főorvos, Siófoki Kórház, Belgyógyászat, Siófok)
  • Gábor SIMONYI (vezető főorvos, Szent Imre Kórház, Anyagcsere Központ, Budapest)
  • Gábor Márk SOMFAI (egyetemi docens, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
  • Anikó SOMOGYI (ny. egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Péter SÓTONYI (professor emeritus, Semmelweis Egyetem, Igazságügyi és Biztosítás-orvostani Intézet, Budapest)
  • Péter Jr. SÓTONYI (egyetemi tanár, Semmelweis Egyetem, Városmajori Szív- és Érsebészeti Klinika, Budapest)
  • Ildikó SÜVEGES (professor emeritus, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
  • György SZABÓ (professor emeritus, Semmelweis Egyetem, Arc-Állcsont-Szájsebészeti és Fogászati Klinika, Budapest)
  • Ferenc SZALAY (professor emeritus, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
  • Miklós SZENDRŐI (professor emeritus, Semmelweis Egyetem, Ortopédiai Klinika, Budapest)
  • István SZILVÁSI (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Miklós TÓTH (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
  • László TRINGER (professor emeritus, Semmelweis Egyetem, Pszichiátriai és Pszichoterápiás Klinika, Budapest)
  • Tivadar TULASSAY (professor emeritus, Semmelweis Egyetem, I. Gyermekgyógyászati Klinika, Budapest)
  • Zsolt TULASSAY (professor emeritus, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Lívia VASAS (ny. könyvtárigazgató, Semmelweis Egyetem, Központi Könyvtár, Budapest)
  • Barna VÁSÁRHELYI (egyetemi tanár, Semmelweis Egyetem, Laboratóriumi Medicina Intézet, Budapest)
  • László VÉCSEI (professor emeritus, Szegedi Tudományegyetem, Neurológiai Klinika, Szeged)
  • Gábor WINKLER (egyetemi tanár, Szent János Kórház, Belgyógyászati Osztály, Budapest)

Nemzetközi szerkesztőbizottság - International Editorial Board:

  • Elnök/President Péter SÓTONYI (Budapest)
  • Ernest ADEGHATE (Al Ain)
  • Ferenc ANTONI (Edinburgh)
  • Maciej BANACH (Łódź)
  • Klára BERENCSI (Rosemont)
  • Angelo BIGNAMINI (Milano)
  • Anupam BISHAYEE (Signal Hill)
  • Hubert E. BLUM (Freiburg)
  • G. László BOROS (Los Angeles)
  • Frank A. CHERVENAK (New York)
  • Meinhard CLASSEN (München)
  • József DÉZSY (Wien)
  • Peter ECKL (Salzburg)
  • Péter FERENCI (Wien)
  • Madelaine HAHN (Erlangen)
  • S. Tamás ILLÉS (Bruxelles)
  • Michael KIDD (Toronto)
  • Andrzej KOKOSZKA (Warsaw)
  • Márta KORBONITS (London)
  • Asim KURJAK (Zagreb)
  • Manfred MAIER (Wien)
  • Neil MCINTYRE (London)
  • Lajos OKOLICSÁNYI (Padova)
  • Amado Salvador PENA (Amsterdam)
  • Guliano RAMADORI (Goettingen)
  • Olivér RÁCZ (Košice)
  • Roberto ROMERO (Detroit)
  • Rainer SCHÖFL (Linz)
  • Zvi VERED (Tel Aviv)
  • Josef VESELY (Olomouc)
  • Ákos ZAHÁR (Hamburg)

Akadémiai Kiadó Zrt. 1117 Budapest
Budafoki út 187-189.
A épület, III. emelet
Phone: (+36 1) 464 8235
Email: orvosihetilap@akademiai.hu

2020  
Total Cites 1277
WoS
Journal
Impact Factor
0,540
Rank by Medicine, General & Internal 155/169 (Q4)
Impact Factor  
Impact Factor 0,310
without
Journal Self Cites
5 Year 0,461
Impact Factor
Journal  0,17
Citation Indicator  
Rank by Journal  Medicine, General & Internal 203/313 (Q4)
Citation Indicator   
Citable 261
Items
Total 229
Articles
Total 32
Reviews
Scimago 21
H-index
Scimago 0,176
Journal Rank
Scimago Medicine (miscellaneous) Q4
Quartile Score  
Scopus 921/1187=0,8
Scite Score  
Scopus General Medicine 494/793 (Q3)
Scite Score Rank  
Scopus 0,283
SNIP  
Days from  28
sumbission  
to acceptance  
Days from  114
acceptance  
to publication  
Acceptance 72%
Rate

2019  
Total Cites
WoS
1 085
Impact Factor 0,497
Impact Factor
without
Journal Self Cites
0,212
5 Year
Impact Factor
0,396
Immediacy
Index
0,126
Citable
Items
247
Total
Articles
176
Total
Reviews
71
Cited
Half-Life
6,1
Citing
Half-Life
7,3
Eigenfactor
Score
0,00071
Article Influence
Score
0,045
% Articles
in
Citable Items
71,26
Normalized
Eigenfactor
0,08759
Average
IF
Percentile
10,606
Scimago
H-index
20
Scimago
Journal Rank
0,176
Scopus
Scite Score
864/1178=0,4
Scopus
Scite Score Rank
General Medicine 267/529 (Q3)
Scopus
SNIP
0,254
Acceptance
Rate
73%

 

Orvosi Hetilap
Publication Model Hybrid
Submission Fee none
Article Processing Charge 900 EUR/article
Printed Color Illustrations 20 EUR (or 5000 HUF) + VAT / piece
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Online subsscription: 844 EUR / 1124 USD
Print + online subscription: 956 EUR / 1326 USD
Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Orvosi Hetilap
Language Hungarian
Size A4
Year of
Foundation
1857
Publication
Programme
2021 Volume 162
Volumes
per Year
1
Issues
per Year
52
Founder Markusovszky Lajos Alapítvány -- Lajos Markusovszky Foundation
Founder's
Address
H-1088 Budapest, Szentkriályi u. 46.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0030-6002 (Print)
ISSN 1788-6120 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Feb 2021 0 5 3
Mar 2021 0 5 12
Apr 2021 0 3 11
May 2021 0 2 6
Jun 2021 0 2 5
Jul 2021 0 1 7
Aug 2021 0 0 0